Relation of resistin to proprotein convertase subtilisin–kexin type 9 levels in coronary artery disease patients with different nutritional status

Li, S.; Xu, Rui‐Xia; Zhang, Y.; Guo, Yuan‐Lin; Zhu, Cheng; Liu, G.; Dong, Qiu‐Ting; Li, J. J.

doi:10.1007/s40618-015-0310-y

Cited by 14 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, resistin was only correlated with PCSK9 concentration in patients with a BMI <35 kg/m 2 . 20 These findings suggest a disruption in PCSK9 concentration in patients with higher adiposity values. Given the mean BMI of the Firefighters and Their Endothelium (FATE) cohort as 28.5±3.6 kg/m 2 , it is possible that the inverse correlation between PCSK9 concentrations and BMI is because of the disruption of the PCSK9 pathway in high BMI subjects.…”

mentioning

confidence: 87%

Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention

Zhu

Anderson

Sikdar

et al. 2015

ATVB

View full text Add to dashboard Cite

P roprotein convertase subtilisin/kexin type 9 (PCSK9) has been recognized for its pivotal role in low-density lipoprotein-cholesterol (LDL-C) metabolism.1-3 PCSK9 plays a key role in the post-translational regulation 4 of hepatic LDLreceptor (LDL-R) activity, with the binding of PCSK9 to LDL-R promoting receptor degradation and impeding the ability of the liver to remove circulating LDL particles. 5,6 Because an elevated plasma concentration of LDL-C has been well established as an atherosclerotic risk factor, 7 PCSK9 presents itself as a potential novel predictor of cardiovascular risk and as a target for lipid-lowering therapy.Flow-mediated dilation (FMD) and carotid intima-media thickness (cIMT) are measures of vascular function and subclinical atherosclerosis 8,9 ; along with reactive hyperemic velocity time integral (VTI), 10 a more recently described marker of microvascular function, these 3 measures have been established as surrogate markers of atherosclerotic risk. The relationship between traditional cardiovascular risk factors and these vascular measures has been well studied, but the impact of PCSK9 concentration on vascular measures has yet to be evaluated. Consequently, this study sought to examine the impact of PCSK9 concentration on measures of vascular function in a population of healthy, middle-aged men. Predictors of PCSK9 concentration and the relationship between the proprotein and the cardiovascular events were also investigated as secondary objectives. Materials and MethodsMaterials and Methods are available in the online-only Data Supplement.© 2015 American Heart Association, Inc. Objective-Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in the modulation of low-density lipoprotein metabolism. This study was conducted to evaluate the relationship between serum PCSK9 concentrations and measures of vascular health, subclinical atherosclerosis, and adverse cardiovascular events. The relationship between traditional risk factors and PCSK9 concentrations was also examined. Approach and Results-The cohort consisted of 1527 middle-aged men enrolled in the Firefighters and Their Endothelium (FATE) study, who were free of vascular disease and followed up over a mean period of 7.2±1.7 years. Baseline evaluation included assessment of traditional cardiovascular risk factors and measurements of flow-mediated dilation, reactive hyperemic velocity time integral, and carotid intima-media thickness. Biochemical parameters, including serum PCSK9 concentrations, were analyzed to determine predictors of vascular measures and to evaluate the role of PCSK9 in the occurrence of adverse cardiovascular events. Multivariate linear regression analyses indicated that body mass index, insulin, low-density lipoprotein-cholesterol, and triglycerides were independent predictors of PCSK9. Further modeling revealed no correlation between PCSK9 concentration and carotid intima media thickness, flow-mediated dilation, or reactive hyperemic velocity time integral. Analyses indicated no signific...

show abstract

mentioning

confidence: 87%

Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention

Zhu

Anderson

Sikdar

et al. 2015

ATVB

View full text Add to dashboard Cite

show abstract

“…Interestingly, according to the structure analysis, PCSK9 C-terminal cysteine-rich domain (CRD) reveals structural homology with resistin (116). Moreover, resistin has also been shown to exhibit a positive correlation with PCSK9 levels by enhancing mRNA expression and protein stability (117, 118). As a result, resistin may act as an activator of PCSK9 in the pathogenesis of psoriasis.…”

Section: Mechanisms Of Mets and Skin Diseasesmentioning

confidence: 99%

Metabolic Syndrome and Skin Diseases

Zhu

Lian

et al. 2019

Front. Endocrinol.

View full text Add to dashboard Cite

The increasing prevalence of Metabolic syndrome (MetS) is a worldwide health problem, and the association between MetS and skin diseases has recently attracted growing attention. In this review, we summarize the associations between MetS and skin diseases, such as psoriasis, acne vulgaris, hidradenitis suppurativa, androgenetic alopecia, acanthosis nigricans, and atopic dermatitis. To discuss the potential common mechanisms underlying MetS and skin diseases, we focus on insulin signaling and insulin resistance, as well as chronic inflammation including adipokines and proinflammatory cytokines related to molecular mechanisms. A better understanding of the relationship between MetS and skin diseases contributes to early diagnosis and prevention, as well as providing clues for developing novel therapeutic strategies.

show abstract

“…Resistin and PCSK9 share a structural homology in the cysteine-rich portion within the C-terminal domain and, thus, it is possible that resistin and PCSK9 form aggregation complexes to target the LDL receptor [59]. In a study investigating a Chinese cohort, plasma resistin levels were significantly related to PCSK9 levels in CAD patients with normal body weight [60]. Taken together, these results indicate that resistin stimulates hepatic VLDL production, increases hepatic lipogenesis, and suppresses LDL receptor levels via increases in hepatocyte PCSK9.…”

Section: Role Of Human Resistin In Atherogenic Dyslipidemiamentioning

confidence: 99%

Linking resistin, inflammation, and cardiometabolic diseases

Park

Kwak

Kim

et al. 2017

Korean J Intern Med

178

150

View full text Add to dashboard Cite

Adipose tissue secretes a variety of bioactive substances that are associated with chronic inflammation, insulin resistance, and an increased risk of type 2 diabetes mellitus. While resistin was first known as an adipocyte-secreted hormone (adipokine) linked to obesity and insulin resistance in rodents, it is predominantly expressed and secreted by macrophages in humans. Epidemiological and genetic studies indicate that increased resistin levels are associated with the development of insulin resistance, diabetes, and cardiovascular disease. Resistin also appears to mediate the pathogenesis of atherosclerosis by promoting endothelial dysfunction, vascular smooth muscle cell proliferation, arterial inflammation, and the formation of foam cells. Thus, resistin is predictive of atherosclerosis and poor clinical outcomes in patients with cardiovascular disease and heart failure. Furthermore, recent evidence suggests that resistin is associated with atherogenic dyslipidemia and hypertension. The present review will focus on the role of human resistin in the pathogeneses of inflammation and obesity-related diseases.

show abstract

Relation of resistin to proprotein convertase subtilisin–kexin type 9 levels in coronary artery disease patients with different nutritional status

Abstract: Plasma resistin was positively related to PCSK9 levels in CAD patients with normal weight, suggesting that the circulating resistin might represent a link with PCSK9 level variations in CAD progression of normal body weight.

Cited by 14 publications

References 31 publications

Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention

Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention

Metabolic Syndrome and Skin Diseases

Linking resistin, inflammation, and cardiometabolic diseases

Contact Info

Product

Resources

About